F

resh off a big clinical trial victory in postpartum depression, Sage Therapeutics (SAGE) announced yet more good news Thursday: Positive results from a mid-stage clinical trial for a pill to treat people with major depressive disorder. The drug appears to work quickly, though its effects diminish over time.

If Thursday’s results are confirmed in later phase 3 clinical trials, the Sage pill, known as SAGE-217, could become one of the first medicines in years with a new mechanism of action to be approved for the treatment of depression.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.